

## EU secures 400 million doses of Janssen's COVID-19 Vaccine Candidate

09 October 2020 | News

**The agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses**



Johnson & Johnson on 8 Oct 2020 announced that the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators. The EU Member States also have the option to secure up to 200 million additional doses.

This contract follows the conclusion of [exploratory talks with the EC](#). The Company is in ongoing discussions with other stakeholders, including national governments and global organizations, as part of its efforts to meet its commitment to make its vaccine candidate accessible globally, provided the vaccine has a good safety profile, is efficacious and receives approval or authorization from regulators.

Separate to the agreement with the EC, as part of the Company's larger commitment to respond to the COVID-19 pandemic, Johnson & Johnson has also announced plans to allocate up to 500 million vaccine doses toward international efforts to ensure access for lower income countries, with delivery beginning mid next year following approval or authorization from regulators.

Johnson & Johnson is developing and testing Janssen's COVID-19 vaccine candidate in accordance with its usual rigorous ethical standards of safety and sound scientific principles. The Company is evaluating a single-dose regimen in its [large-scale, pivotal, multi-country Phase 3 trial \(ENSEMBLE\)](#) that started in September. A second Phase 3 study with a two-dose regimen is planned to start later this year. The Company is committed to transparency and sharing information related to the Phase 3 ENSEMBLE study – including the study protocol. Janssen's investigational COVID-19 vaccine leverages Janssen's AdVac<sup>®</sup> technology.